Table 2. Outcome results according to immunohistochemical expression in platinum (N=56) vs non-platinum (N=50) regimens.

	ERCC1		BRCA1
	Positive	Negative	Positive	Negative
	No. 58	No. 48	No. 56	No. 53
RR (%)
P	14.8	58.6	43.3	30.8
Non-P	22.6	31.6	26.9	22.2
OR (95% CI)	0.58 (0.15–2.27)	3.19 (0.93–10.91)	2.11 (0.66–6.56)	1.52 (0.44–5.25)
P-valuea	0.071		0.704
Median PFS (mos)
P	4.4 (2.6–7.4)	7.1 (6.3–9.7)	7.2 (4.4–9.1)	6.5 (3.2–7.0)
Non-P	4.1 (2.9–6.7)	7.9 (3.8–9.3)	5.0 (3.8–8.7)	4.3 (2.6–7.3)
HR (95% CI)	0.93 (0.55–1.57)	0.93 (0.52–1.70)	0.90 (0.53–1.54)	0.76 (0.44–1.31)
P-valuea	0.984		0.654
Median OS (mos)
P	7.8 (3.0–9.8)	15.7 (11.2–20.4)	14.9 (7.1–19)	9.5 (5.8–15.4)
Non-P	10.3 (5.1–13.8)	23.8 (11.3–28.5)	13.5 (9.4–23.3)	11.3 (6.0–17.0)
HR (95% CI)	1.39 (0.81–2.37)	1.01 (0.55–1.85)	1.11 (0.65–1.91)	1.04 (0.60–1.80)
P-valuea	0.446		0.855

Abbreviations: BRCA1=breast cancer 1; CI=confidence interval; ERCC1=excision repair cross-complementing 1; HR=hazard ratio; mos=months; non-P=non-platinum; OR=odds ratio; OS=overall survival; P=platinum; PFS=progression-free survival; RR=response rate.

^aTest of interaction.